Jump to content

Ombitasvir: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
No edit summary
mNo edit summary
Line 51: Line 51:
}}
}}


'''Ombitasvir''' is an [[antiviral drug]] for the treatment of [[hepatitis C virus]] (HCV) infection. In the United States, it is approved by the [[Food and Drug Administration]] for use in combination with [[paritaprevir]], [[ritonavir]] and [[dasabuvir]] in the products [[Viekira Pak]] (for the treatment of HCV genotype 1)<ref>{{cite web|title=VIEKIRA PAK™ (ombitasvir, paritaprevir and ritonavir tablets; dasabuvir tablets), for Oral Use. Full Prescribing Information|url=http://www.rxabbvie.com/pdf/viekirapak_pi.pdf|publisher=AbbVie Inc., North Chicago, IL 60064|accessdate=30 July 2015}}</ref><ref>{{Cite web | title = FDA approves Viekira Pak to treat hepatitis C | url = http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427530.htm | date = December 19, 2014 | publisher = [[Food and Drug Administration]]}}</ref> and Technivie (for the treatment of HCV genotype 4)<ref>{{cite web|title=TECHNIVIE™ (ombitasvir, paritaprevir and ritonavir) Tablets, for Oral Use. Full Prescribing Information|url=http://rxabbvie.com/pdf/technivie_pi.pdf|publisher=AbbVie Inc., North Chicago, IL 60064|accessdate=28 July 2015}}</ref><ref>{{Cite web | title = FDA approves Technivie for treatment of chronic hepatitis C genotype 4 | url = http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm455857.htm | date = July 24, 2015 | publisher = [[Food and Drug Administration]]}}</ref>.
'''Ombitasvir''' is an [[antiviral drug]] for the treatment of [[hepatitis C virus]] (HCV) infection. In the United States, it is approved by the [[Food and Drug Administration]] for use in combination with [[paritaprevir]], [[ritonavir]] and [[dasabuvir]] in the product [[Viekira Pak]] for the treatment of HCV genotype 1<ref>{{cite web|title=VIEKIRA PAK™ (ombitasvir, paritaprevir and ritonavir tablets; dasabuvir tablets), for Oral Use. Full Prescribing Information|url=http://www.rxabbvie.com/pdf/viekirapak_pi.pdf|publisher=AbbVie Inc., North Chicago, IL 60064|accessdate=30 July 2015}}</ref><ref>{{Cite web | title = FDA approves Viekira Pak to treat hepatitis C | url = http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427530.htm | date = December 19, 2014 | publisher = [[Food and Drug Administration]]}}</ref>, and with [[paritaprevir]] and [[ritonavir]] in the product Technivie for the treatment of HCV genotype 4<ref>{{cite web|title=TECHNIVIE™ (ombitasvir, paritaprevir and ritonavir) Tablets, for Oral Use. Full Prescribing Information|url=http://rxabbvie.com/pdf/technivie_pi.pdf|publisher=AbbVie Inc., North Chicago, IL 60064|accessdate=28 July 2015}}</ref><ref>{{Cite web | title = FDA approves Technivie for treatment of chronic hepatitis C genotype 4 | url = http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm455857.htm | date = July 24, 2015 | publisher = [[Food and Drug Administration]]}}</ref>.


Ombitasvir acts by inhibiting the HCV protein [[NS5A]].<ref>{{Cite journal | title = Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin | author = Jordan J. Feld, Kris V. Kowdley, Eoin Coakley, Samuel Sigal, David R. Nelson, Darrell Crawford, Ola Weiland, Humberto Aguilar, Junyuan Xiong, Tami Pilot-Matias, Barbara DaSilva-Tillmann, Lois Larsen, Thomas Podsadecki, and Barry Bernstein | journal = N Engl J Med| date = 2014 | volume = 370 | pages = 1594–1603 | doi = 10.1056/NEJMoa1315722}}</ref>
Ombitasvir acts by inhibiting the HCV protein [[NS5A]].<ref>{{Cite journal | title = Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin | author = Jordan J. Feld, Kris V. Kowdley, Eoin Coakley, Samuel Sigal, David R. Nelson, Darrell Crawford, Ola Weiland, Humberto Aguilar, Junyuan Xiong, Tami Pilot-Matias, Barbara DaSilva-Tillmann, Lois Larsen, Thomas Podsadecki, and Barry Bernstein | journal = N Engl J Med| date = 2014 | volume = 370 | pages = 1594–1603 | doi = 10.1056/NEJMoa1315722}}</ref>

Revision as of 19:00, 29 July 2015

Ombitasvir
Clinical data
Trade namesViekira Pak (with ombitasvir, paritaprevir, ritonavir and dasabuvir), Technivie (with ombitasvir, paritaprevir, and ritonavir)
Other namesABT-267
Routes of
administration		Oral
Legal status
Legal status
Pharmacokinetic data
Bioavailabilitynot determined
Protein binding~99.9%
Metabolismamide hydrolysis followed by oxidation
Onset of action~4 to 5 hours
Elimination half-life21 to 25 hours
Excretionmostly with feces (90.2%)
Identifiers
  • Dimethyl ({(2S,5S)-1-[4-(2-methyl-2-propanyl)phenyl]-2,5-pyrrolidinediyl}bis{4,1-phenylenecarbamoyl(2S)-2,1-pyrrolidinediyl[(2S)-3-methyl-1-oxo-1,2-butanediyl]})biscarbamate
CAS Number
PubChem CID
ChemSpider
ChEBI
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC50H67N7O8
Molar mass894.11 g/mol g·mol−1
3D model (JSmol)
  • CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)Nc2ccc(cc2)[C@@H]3CC[C@H](N3c4ccc(cc4)C(C)(C)C)c5ccc(cc5)NC(=O)[C@@H]6CCCN6C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC
  • InChI=1S/C50H67N7O8/c1-30(2)42(53-48(62)64-8)46(60)55-28-10-12-40(55)44(58)51-35-20-14-32(15-21-35)38-26-27-39(57(38)37-24-18-34(19-25-37)50(5,6)7)33-16-22-36(23-17-33)52-45(59)41-13-11-29-56(41)47(61)43(31(3)4)54-49(63)65-9/h14-25,30-31,38-43H,10-13,26-29H2,1-9H3,(H,51,58)(H,52,59)(H,53,62)(H,54,63)/t38-,39-,40-,41-,42-,43-/m0/s1
  • Key:PIDFDZJZLOTZTM-KHVQSSSXSA-N

Ombitasvir is an antiviral drug for the treatment of hepatitis C virus (HCV) infection. In the United States, it is approved by the Food and Drug Administration for use in combination with paritaprevir, ritonavir and dasabuvir in the product Viekira Pak for the treatment of HCV genotype 1[1][2], and with paritaprevir and ritonavir in the product Technivie for the treatment of HCV genotype 4[3][4].

Ombitasvir acts by inhibiting the HCV protein NS5A.[5]

References

  1. ^ "VIEKIRA PAK™ (ombitasvir, paritaprevir and ritonavir tablets; dasabuvir tablets), for Oral Use. Full Prescribing Information" (PDF). AbbVie Inc., North Chicago, IL 60064. Retrieved 30 July 2015.
  2. ^ "FDA approves Viekira Pak to treat hepatitis C". Food and Drug Administration. December 19, 2014.
  3. ^ "TECHNIVIE™ (ombitasvir, paritaprevir and ritonavir) Tablets, for Oral Use. Full Prescribing Information" (PDF). AbbVie Inc., North Chicago, IL 60064. Retrieved 28 July 2015.
  4. ^ "FDA approves Technivie for treatment of chronic hepatitis C genotype 4". Food and Drug Administration. July 24, 2015.
  5. ^ Jordan J. Feld, Kris V. Kowdley, Eoin Coakley, Samuel Sigal, David R. Nelson, Darrell Crawford, Ola Weiland, Humberto Aguilar, Junyuan Xiong, Tami Pilot-Matias, Barbara DaSilva-Tillmann, Lois Larsen, Thomas Podsadecki, and Barry Bernstein (2014). "Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin". N Engl J Med. 370: 1594–1603. doi:10.1056/NEJMoa1315722.{{cite journal}}: CS1 maint: multiple names: authors list (link)


Stub icon

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Ombitasvir&oldid=673675072"